Securing the Pipeline: Can-Fite's Strategic Pivot Ahead of Phase III Data

RAMAT GAN, Israel – November 06, 2026 – In the modern enterprise, risk mitigation is often treated as a cybersecurity or supply chain imperative. But in the high-stakes arena of clinical-stage biotechnology, corporate security is defined by capital runway and strategic alliances. As binary Phase III data readouts loom on the horizon, Israel-based Can-Fite BioPharma is executing a classic enterprise derisking maneuver: leveraging late-stage clinical data and an expanding intellectual property moat to secure global pharmaceutical partnerships.

The company announced today its deployment to BIO-Europe 2026 in Cologne, Germany, signaling a critical transition phase. With two pivotal Phase III trials underway and fresh Phase IIa data in pancreatic cancer, Can-Fite is aggressively pursuing licensing agreements, co-development frameworks, and commercialization partnerships. For a small-cap biotech navigating the capital-intensive final stages of drug development, securing non-dilutive funding through strategic alliances is not merely a growth strategy—it is a fundamental requirement for corporate sustainability.

The Calculus of Non-Dilutive Capital

To understand Can-Fite's aggressive business development push, one must look at the financial architecture of clinical-stage drug development. Developing small-molecule drugs targeting oncological and inflammatory diseases requires massive capital expenditure. As of mid-2026, Can-Fite reported approximately $7.03 million in cash and cash equivalents, supplemented by a recent $4.0 million warrant exercise in September. While this provides operational runway, advancing multiple late-stage trials simultaneously accelerates cash burn.

Rather than resorting to highly dilutive equity raises—a move that frequently punishes shareholders in the current macroeconomic environment—Can-Fite is leaning on its proven ability to monetize its pipeline. The company has already generated approximately $20 million in non-dilutive upfront and milestone payments through regional licensing agreements.

Notable deals include a comprehensive pact with China Medical System Holdings Limited (CMS) for rights in the Chinese market, and an exclusive distribution agreement with Switzerland-based Ewopharma AG covering Central Eastern Europe and Switzerland. Earlier this year, the Ewopharma agreement was expanded to include Namodenoson for pancreatic cancer. The objective at BIO-Europe is to replicate and scale this model, seeking tier-one pharmaceutical partners capable of providing both the capital to cross the clinical finish line and the global commercial infrastructure required for a successful launch.

Monetizing Early Signals in Hard-to-Treat Cancers

The cornerstone of Can-Fite's oncology pitch centers on Namodenoson, a highly selective oral agonist of the A3 adenosine receptor (A3AR). In an oncology landscape dominated by checkpoint inhibitors and complex biologics, a differentiated small-molecule approach offers a distinct strategic advantage.

Can-Fite arrives at BIO-Europe armed with final positive Phase IIa data for Namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC), recently presented at the ESMO 2026 Congress in Madrid. Pancreatic cancer remains one of the most notoriously difficult malignancies to treat, characterized by a highly immunosuppressive tumor microenvironment. The open-label study, while small with 20 patients, demonstrated a favorable safety profile and encouraging exploratory survival benefits in heavily pretreated patients.

Notably, a post-hoc analysis of third-line patients who survived beyond two months showed a median overall survival of 6.28 months. Furthermore, one second-line patient achieved a prolonged overall survival exceeding 20 months. While these findings are hypothesis-generating and require validation in larger randomized trials, they provide a compelling narrative for prospective partners seeking novel mechanisms of action in gastrointestinal oncology.

Simultaneously, Namodenoson is being evaluated in the pivotal Phase III LIVERATION trial for advanced hepatocellular carcinoma (HCC). The trial specifically targets patients with underlying Child-Pugh B7 cirrhosis—a niche population with significant unmet medical needs. In a highly strategic disclosure, Can-Fite recently announced that blinded overall survival across the entire study population appears longer than originally anticipated. While the data remains blinded, precluding definitive conclusions about efficacy, this signal has prompted the company to evaluate an earlier interim analysis. For pharmaceutical business development executives, this longer-than-expected survival trend serves as a potent catalyst for deal-making discussions.

The Psoriasis Battlefield and IP Expansion

Beyond oncology, Can-Fite is navigating the fiercely competitive immunology market with Piclidenoson, another A3AR agonist currently in a pivotal Phase III trial for moderate-to-severe plaque psoriasis. The trial has successfully completed enrollment of the 247 patients required for a prespecified interim analysis, with efficacy and safety data expected in the first quarter of 2027.

The psoriasis market is a high-volume, high-value battleground currently dominated by injectable biologics and established oral therapies like Otezla and newer entrants like Sotyktu. To successfully commercialize an oral therapy in this crowded space, a massive global sales force and deep payer contracting expertise are required. Can-Fite's push at BIO-Europe is driven by the reality that competing in the psoriasis market necessitates a heavyweight pharmaceutical partner. Piclidenoson's value proposition rests on a differentiated mechanism of action—inhibiting inflammatory cytokines like IL-17 and IL-23 by targeting the A3AR—and a remarkably clean safety profile demonstrated in over 1,500 clinical subjects, which could position it favorably for chronic, long-term use.

Bolstering the attractiveness of its pipeline, Can-Fite is also aggressively expanding its intellectual property moat. Just days prior to the BIO-Europe conference, the company announced a notification of readiness to grant a Eurasian patent covering the use of Piclidenoson for diseases associated with OCRL deficiency, specifically Lowe syndrome and Dent disease 2. This rare disease application, supported by a collaboration with Fondazione Telethon, opens a new, highly specialized vertical for potential partners who focus on orphan indications with premium pricing dynamics.

The BIO-Europe Proving Ground

"BIO-Europe provides an important opportunity to translate our recent clinical and intellectual property progress into strategic business discussions," stated Dr. Sari Fishman, Vice President of Business Development at Can-Fite. "With two pivotal Phase III programs, encouraging new clinical data in pancreatic cancer, and an expanding portfolio of development and commercialization opportunities, we believe Can-Fite offers potential partners access to differentiated clinical-stage assets."

Dr. Fishman's remarks underscore the overarching corporate strategy: transforming clinical milestones into tangible commercial value. As the biotechnology sector faces intense scrutiny over capital allocation and clinical trial execution, companies like Can-Fite must operate with the precision of a seasoned enterprise software firm securing enterprise contracts.

The coming days in Cologne will be a critical proving ground. The company's ability to secure comprehensive licensing and co-development agreements will not only validate the scientific merit of its A3AR platform but also dictate its financial trajectory as it approaches the binary risks of 2027. In the modern biopharmaceutical ecosystem, scientific innovation is only the first step; strategic business architecture is what ultimately delivers therapies to patients and value to shareholders.